Foghorn Therapeutics Reports Breakthrough Progress in Selective ARID1B Degrader for Cancer Treatment
核心洞察
Foghorn Therapeutics announced significant progress for its selective ARID1B degrader (搜索) program targeting endometrial, gastric, and bladder cancers with high unmet medical needs.
The company will present breakthrough findings at the 8th Annual TPD and Induced Proximity Summit as part of a keynote plenary session on October 29, 2025.
Foghorn's selective CBP and EP300 degrader programs are progressing toward Investigational New Drug enabling studies, expanding the company's protein degrader pipeline.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced significant progress for its selective ARID1B degrader (搜索) program, positioning the clinical-stage biotechnology company to present breakthrough findings at the 8th Annual TPD and Induced Proximity Summit in Boston. The company's advances target endometrial, gastric, and bladder cancers with high unmet medical needs through a novel approach to protein degradation.
Keynote Presentation Highlights Novel Cancer Treatment Approach
The Cambridge-based company will showcase its selective ARID1B degrader (搜索) program during a keynote plenary session titled "Harnessing Degradation to Achieve Selectivity & First-in-Class Targeting of Challenging Chromatin Regulatory Proteins" on October 29, 2025. Steven Bellon, Chief Scientific Officer of Foghorn Therapeutics, will present the findings at 3:45 p.m. EDT.
"We are excited to present significant progress for our Selective ARID1B degrader (搜索) at this year's TPD and Induced Proximity Summit," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. "These findings highlight the potential of our Selective ARID1B degrader program to become a new class of drugs for patients with endometrial, gastric, and bladder cancers with high unmet needs."
Expanding Pipeline Shows Promise for Multiple Cancer Types
Beyond the ARID1B (搜索) program, Foghorn is advancing two additional selective degrader programs targeting CBP and EP300 proteins. These programs are progressing toward Investigational New Drug (IND) enabling studies, representing continued momentum in the company's protein degrader capabilities.
"At our virtual investor event, we will share the continued momentum for our Selective CBP and Selective EP300 degrader (搜索) programs, which are steadily progressing toward Investigational New Drug (IND) enabling studies," Gottschalk noted. "These collective developments reflect the potential of our protein degrader capabilities to expand therapeutic possibilities in areas with limited treatment innovation."
Gene Traffic Control Platform Drives Innovation
Foghorn's approach centers on its proprietary scalable Gene Traffic Control platform, which systematically studies, identifies, and validates potential drug targets within the chromatin regulatory system. The company focuses on discovering and developing medicines that target genetically determined dependencies within this system to treat serious diseases by correcting abnormal gene expression.
Investor Engagement and Future Outlook
Following the scientific presentation, Foghorn will host a virtual investor event on October 30, 2025, at 12 p.m. EDT to provide comprehensive pipeline updates for its selective ARID1B (搜索), CBP, and EP300 degrader programs. The presentation will be accessible on the company's website, with both live webcast and replay options available for stakeholders.
The developments position Foghorn as a pioneer in targeting challenging chromatin regulatory proteins through selective degradation, potentially opening new therapeutic avenues for cancer patients with limited treatment options.